A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy

Protocol: 
AAAO1055
Phase: 
I

A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy

The purpose of this study is to evaluate the safety and drug profile of ABT-199 administered orally in combination with azacitidine or decitabine in patients who are not eligible for standard induction therapy and have not been previously treated for Acute Myelogenous Leukemia.

Are you Eligible? (Inclusion Criteria)

1) Greater than or equal to 65 years old
2) Not eligible for standard induction therapy (cytarabine and anthracycline)
3) No prior treatment for Acute Myelogenous Leukemia (treatment for prior Myelodysplastic Syndrome allowed, excluding hypomethalating agents

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States